NanoSphere Health Sciences Achieves Landmark Patent
April 10th, 2018
Exclusive, News, Top News
Researchers might know that active pharmaceutical ingredients produce a certain result in cells, but they often face difficulty delivering those APIs to target areas within the body. Many of the most promising companies in the biotech and pharmaceutical spaces are focused on developing drug delivery technologies designed to bring precise doses of APIs to highly specific targets without being degraded by the liver, digestive system or other parts of the body.
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) recently announced that the United States Patent and Trademark Office granted Patent No. 9,925,149 covering the core technology behind the production of its NanoSphere Delivery System™, which paves the way for commercialization of its breakthrough delivery technology. Investors may want to take a closer look at the stock given these catalysts.
NanoSphere Delivery System
NanoSphere Health Sciences’ NanoSphere Delivery System™ is one of the most important advancements for the non-invasive delivery of biological agents in over 25 years. By nanoencapsulating a broad range of bioactive compounds in a protective, lipid membrane, the delivery platform transports them rapidly and effectively into the bloodstream and cells, while also making the active ingredients safer and more bioavailable by delivering precise doses to target sites.
The cannabis industry may be legal across much of North America, but physicians and patients have struggled to accurately prescribe the drug even if they know it’s safe and efficacious. For example, researchers have found that the bioavailability of cannabinoids differs greatly between individuals and delivery methods. The company’s NanoSphere Delivery System™ can help bypass first-pass metabolism and enhance and stabilize the bioavailability of cannabinoids.
In addition to cannabis, the NanoSphere Delivery System™ can be applied to many different hard-to-absorb nutrients, such as fat-soluble vitamins, fatty acids, minerals, botanical extracts, and phytochemicals. The technology could help increase bioavailability of these agents compared to traditional methods without the need to swallow capsules or take tinctures. These benefits could be enormous in the multi-billion dollar nutraceutical industry.
Building an IP Portfolio
NanoSphere Health Sciences’ new patent broadly covers the formation and manufacturing of lipid, structural nanoparticles, which is the NanoSphere Delivery System™, for the delivery of cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals, and other biological agents. In particular, the patent extends to its 16 forms of lipid nanoparticle structures, which can be applied across healthcare sectors for vastly improved delivery of active pharmaceutical ingredients.
“The granting of the patent for the NanoSphere Delivery System™ secures our position as a leader in advanced nanoparticle delivery,” said NanoSphere Health Sciences CEO Robert Sutton in the press release announcing the new patent. “Major industries have the potential to be reshaped and reimagined by our next-generation technology.”
With the new patent, NanoSphere Health Sciences will have long-term market exclusivity over the delivery platform. The company plans to license the patented NanoSphere Delivery System™ and its proprietary manufacturing process to select companies in its target industries to maximize commercialization. The patent also enables the company to develop its own product lines, including Evolve Formulas’ transdermal, intranasal, and intraoral cannabis applications.
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) represents a compelling investment opportunity in the drug delivery space. With its new patent in place, the company is well-positioned to commercialize its breakthrough technology in both the cannabis industry and the wider nutraceutical and pharmaceutical industries. Keep an eye NanoSphere as it pursues opportunities in these potentially lucrative markets.
For more information, visit the company’s website at www.nanospherehealth.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.